AZ and Incyte investigate combo therapy for NSCLC
AstraZeneca PLC and Incyte Corp. have come together again, this time to study a combination of Incyte's INCB39110 with AZ's Tagrisso (osimertinib) for non-small cell lung cancer.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.